NEW YORK, Oct. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Triple Analysis: Breast Cancer, Cancer Vaccines and Antibodies
http://www.reportlinker.com/p0284807/Triple-Analysis-Breast-Cancer-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Breast Cancer
The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer.
This part is based on the following publication:
Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
Part II: Cancer Vaccines
The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications.
This part is based on the following publication:
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Key Topics Covered:
Part I: Breast Cancer
5.1 The Scope of this Report 29
6 Consider the Therapeutic Breast Cancer Target for the Highest Therapeutic Outcome and Return on Investment (207 Drug Targets) 33-376
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline? (193 Drug Target Strategies and 405 Drugs) 377-441
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 442-488
9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Therapeutic Pipeline by Investigator (220 Investigators) 489-891
11 Drug Index 893
12 Company Index 905
Figures: Includes 7 Figures
Tables: Includes 274 Tables
Total Number of Pages: 913
Part II: Cancer Vaccines
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets) 30-194
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs) 195-308
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 309-338
9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications) 339-386
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators) 387-649
11 Disclaimer 650
12 Drug Index 651
13 Company Index 656
Figures: Includes 6 Figures
Tables: Includes 205 Tables
Total Number of Pages: 659
Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (255 Drug Targets) 39-430
7 Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug Targets Strategies and 531 Antibody Drugs) 431-768
8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications) 769-893
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531 Antibody Drugs) 894-1,916
10 Disclaimer 1917
11 Drug Index 1918
12 Company Index 1934
Figures: Includes 5 Figures
Tables: Includes 347 Tables
Total Number of Pages: 1,944
To order this report:
Drug and Medication Industry: Triple Analysis: Breast Cancer, Cancer Vaccines and Antibodies
Drug and Medication Business News
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article